1. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Issue 10191 (29th June 2019) Authors: Earl, Helena M; Hiller, Louise; Vallier, Anne-Laure; Loi, Shrushma; McAdam, Karen; Hughes-Davies, Luke; Harnett, Adrian N; Ah-See, Mei-Lin; Simcock, Richard; Rea, Daniel; Raj, Sanjay; Woodings, Pamela; Harries, Mark; Howe, Donna; Raynes, Kerry; Higgins, Helen B; Wilcox, Maggie; Plummer, Chris; Ma... Journal: Lancet Issue: Volume 393:Issue 10191(2019) Page Start: 2599 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Issue 1 (January 2020) Authors: Mateo, Joaquin; Porta, Nuria; Bianchini, Diletta; McGovern, Ursula; Elliott, Tony; Jones, Robert; Syndikus, Isabel; Ralph, Christy; Jain, Suneil; Varughese, Mohini; Parikh, Omi; Crabb, Simon; Robinson, Angus; McLaren, Duncan; Birtle, Alison; Tanguay, Jacob; Miranda, Susana; Figueiredo, Ines; Seed... Journal: Lancet oncology Issue: Volume 21:Issue 1(2020) Page Start: 162 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Primary Chemotherapy for Inoperable Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without Delayed Debulking Surgery. Issue 4 (1st May 2012) Authors: Saha, Antonio; Varughese, Mohini; Gallagher, Chris J.; Orphanos, George; Wilson, Peter; Oram, David; Jeyarajah, Arjun; Reynolds, Karina; Shepherd, John; McCormack, Mary; Olaitan, Adeola; McDonald, Nicola; Mould, Tim; McNeish, Iain; Ledermann, Jonathan A. Journal: International journal of gynecological cancer Issue: Volume 22:Issue 4(2012) Page Start: 566 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. Issue 3 (March 2023) Authors: Brown, Janet E; Royle, Kara-Louise; Gregory, Walter; Ralph, Christy; Maraveyas, Anthony; Din, Omar; Eisen, Timothy; Nathan, Paul; Powles, Tom; Griffiths, Richard; Jones, Robert; Vasudev, Naveen; Wheater, Matthew; Hamid, Abdel; Waddell, Tom; McMenemin, Rhona; Patel, Poulam; Larkin, James; Faust, G... Journal: Lancet oncology Issue: Volume 24:Issue 3(2023) Page Start: 213 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗